AN2 Therapeutics, Inc.
ANTX
$1.26
-$0.02-1.56%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -51.32M | -60.70M | -64.66M | -66.03M | -64.73M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.06M | 4.77M | 5.13M | 5.25M | 5.61M |
| Change in Net Operating Assets | -3.00M | -5.13M | -1.32M | 1.49M | 5.83M |
| Cash from Operations | -49.26M | -61.05M | -60.85M | -59.29M | -53.29M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 54.59M | 61.89M | -19.29M | -27.88M | -43.28M |
| Cash from Investing | 54.59M | 61.89M | -19.29M | -27.88M | -43.28M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 372.00K | 372.00K | 66.42M | 85.47M | 85.32M |
| Repurchase of Common Stock | -- | -321.00K | -321.00K | -321.00K | -321.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 372.00K | 51.00K | 66.09M | 85.14M | 84.99M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 5.70M | 888.00K | -14.04M | -2.02M | -11.57M |